

# Creation of the Pediatric Data & Safety Monitoring Committee: Providing Pediatric Expertise and Independent Oversight for MSK-Sponsored Pediatric Studies

Diana Diaz-Leyton, MHA, Xhenete Lekperic, Krista Napolitano, MA, Christina Kolenut, MPH, Sara Hanley, MSW, Ann Rodavitch, MA, Collette Houston, Brigitte Widemann, MD, Julia Glade Bender, MD

# Background

- In accordance with Cancer Center Support Grant (CCSG) guidelines, Memorial Sloan Kettering (MSK) follows a structured Data and Safety Monitoring Plan (DSMP) for oversight of investigatorinitiated trials (IITs).
- Historically, the Data and Safety Monitoring Committee (DSMC) and Data and Safety Monitoring Board (DSMB) monitored all applicable MSK-sponsored IITs, including pediatric studies.
- As MSK's pediatric research portfolio expanded, the need for specialized, independent oversight to enhance objectivity, reduce institutional bias, and improve transparency became evident.

## Goals


Enhance institutional data and safety monitoring (DSM) strategy by integrating specialized, independent oversight for pediatric IITs.

### Methods

## **Established the Pediatric Data and Safety Monitoring Committee** (PDSMC) as an Independent Oversight Committee:


- · Defined scope and responsibilities: To enhance pediatric IIT monitoring, focusing on safety, data integrity, study progress, and compliance.
- Appointed committee leadership, with an external chair for unbiased oversight and regulatory compliance, and two internal chairs for institutional coordination.
- Recruited predominately external pediatric oncologists and statisticians for specialized oversight.
- Streamlined external member onboarding (e.g., legal agreements) to improve efficiency.


# Integrated Pediatric-Specific Workflows into MSK's DSM Strategy:



- Developed Standard Operating Procedures (SOPs) to formalize committee structure, scope, decision-making, and review criteria.
- Defined monitoring criteria to determine which studies require PDSMC oversight.
- Transitioned eligible pediatric studies from DSMC to PDSMC for specialized review.
- Implemented a quarterly meeting schedule to comply with institutional DSMP.
- Leveraged Tableau activation dashboards to identify new studies requiring PDSMC oversight.
- Implemented a pipeline tracker to ensure timely monitoring of new studies and track existing studies.

# Figure 1: PDSMC Monitoring Form Excerpt





**Outcomes** 

- Expanding MSK's pediatric DSM expertise by increasing pediatric DSM reviewers from 1 to 9 (Figure 3), which enhanced specialized oversight.
- Strengthening external engagement at MSK by nearly tripling the number of external experts (Figure 4) across DSM committees (from 5 to 14), enriching multidisciplinary input and expertise.
- Improving standardization with structured review tools tailored to pediatric studies for clearer expectations and consistent submissions.

## Figure 2: PDSMC Reviewer Checklist Excerpt

1.	Previous Review: Are there any concerns with how				
	comments from the last PDSMC review have been	Yes	No	o N/A	
	addressed?				
2.	Data: Are there issues with data integrity? (e.g., data	Yes		No	
	analyses conducted to date, database compliance, sufficient				
	data entry, site data reporting, etc.)				
3.	Compliance: Are there concerns with adherence to the	Yes		No	
	protocol's biostatistical plan? (e.g., design/statistical				
	compliance [achieve endpoints, interim analysis], data				
	collection/management, etc.)				
4.	Study Progress: Are there concerns with the study				
	progressing as planned and meeting its objectives?	Yes		No	No
	(e.g., accrual, site progress, large number of inevaluable			NO	
	participants, etc.)				
5.	Safety: Are there concerns with the safety of the trial	Yes		No	No
	(e.g., toxicity trends, dosing)?			110	
6.	Risk/Benefit: Are there concerns with the potential	Yes		No	
	benefit to study participants?			No	110

Figure 4: External Expertise Across DSM Committees




Figure 3: Expansion of Pediatric DSM Expertise

DSMC

PDSMC



# Implemented Standardized Tools Modeled after DSMC/B Templates:

- Created a PDSMC Monitoring Form (Figure 1) to standardize submissions. The form ensures consistency in capturing study/design overview and updates, enrollment data, data integrity metrics, safety metrics and analysis data.
- Designed a Reviewer Checklist (Figure 2) to enhance focus, consistency, and standardization across committee evaluations.

# **Ensured Member Training and Engagement:**

- Developed structured training materials to align members with institutional expectations and DSM best practices.
- Engaged members in the creation of key operational tools (e.g., SOPs, Form), ensuring collaborative and transparent committee operations.
- Conducted onboarding sessions to ensure effective participation and alignment with newly established workflows.

# 2024 2021 2023 2022 Pre-PDSMC Post-PDSMC

### **Lessons Learned**

- Training materials must be tailored to provide institutional context for external members.
- Standardizing legal onboarding workflows reduce bottlenecks and delays.

## **Future Directions**

- Expand PDSMC portfolio.
- Expand PDSMC membership expertise (e.g., hematology).
- Leverage technology to enhance coordination and efficiency.
- Strengthen ongoing education and training for members.